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group (67% vs. 41%, p0.01). In particular this difference stemmed from an increase of
access site-related bleeding (21% vs. 7%, p0.01) and cardiac death (41% vs. 25%,
p0.01) in the FF group. The adjusted multivariable regression analysis confirmed radial
approach as independent outcome predictor (OR 0.53 CI 95% 0.29-0.96, p0.037).
Conclusions: Transradial approach use for PCI requiring IABP support positively
impacts periprocedural outcome by means of a significant access-site-related bleeding and
cardiac death prevention. Thus, its use seems strongly recommended in patients at
increased risk of bleeding, such as those admitted for an ACS.
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Background: There has been a significant increase in use of transradial access (TRA) for
PCI in the UK. Early on in the TRA learning curve, procedures are associated with more
catheter exchanges, longer screening times and with more contrast use. These factors are
all associated with increased risk of periprocedural neurological complications (NC).
Using the British Cardiovascular Intervention Society PCI database we assessed changes in
NC through a period of transition during which radial access became the dominant access for
PCI.
Methods: This study includes data collected by the British Cardiovascular Intervention
Society under the auspices of the Central Cardiac Audit Database. We performed a
retrospective analysis of the BCIS database between January 2006 and December 2010.
The data was split into 2 cohorts based on access site: either radial or femoral (mixed
access site use and other access sites were excluded from the analysis). A NC was defined
as a periprocedural TIA, ischemic stroke or hemorrhagic stroke.
Results: Between 2006 and 2010 a total of 348,092 procedures were recorded exclusively
using either transradial (TRA) or tansfemoral (TFA) access. Over 5 years, the use of TRA for
PCI increased from 17.1% to 50.8% of procedures. There was no difference in the incidence
of NC during this period. Following multivariate analysis of the whole 5 year cohort, no
difference in NC was observed between TRA and TFA (HR 1.005 CI 0.81-1.248: p0.96).
Conclusions: These results are reassuring and suggest that a switch from TFA to TRA
is not associated with any increased risk of periprocedural neurological complications.
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Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary
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Background: The everolimus-eluting Bioresorbable Vascular Scaffold (Absorb) is a
novel approach to treating coronary lesions. A persistent inflammatory response, fibrin
deposition and delayed endothelialisation have been reported with overlapping first-
generation drug eluting stents. We report optical coherence tomography and histological
findings in a porcine coronary artery model after implantation of overlapping Absorb or
second-generation everolimus-eluting metallic platform stents (XIENCE V [XV]).
Methods: 41 overlapping Absorb and overlapping XV devices (3.012 mm) were
implanted in the main coronary arteries of 17 non-atherosclerotic pigs with a balloon
artery ratio of 1.1:1 (10% over-stretch). Implanted coronary arteries were evaluated by
OCT at 28 (Absorb: n11, XV: n 7) and 90 days (Absorb: n11, XV: n 8), with
immediate histological evaluation following euthanasia at the same time points. One
animal from each time point was evaluated with scanning electron microscopy alone.
Results: 1407 cross-sections were analysed by OCT and 148 cross-sections analysed
histologically. At 28 days in the overlap, OCT analyses indicated 80.1% of Absorb struts
and 99.4% of XV struts to be covered (p0.0001), corresponding to histological
observations of struts with cellular coverage of 75.4% and 99.6% respectively (p0.001).
Uncovered struts were almost exclusively related to the presence of ’stacked’ Absorb
struts, i.e. with a direct overlay configuration. At 90 days overlapping Absorb and
overlapping XV struts demonstrated99% strut coverage by OCT and histology, with no
evidence of a significant inflammatory process, and comparable % volume obstructions.
Conclusions: In porcine coronary arteries implanted with overlapping Absorb, strut
coverage is dependent on the overlay configuration of Absorb struts at 28 days and not at
90 days. The potential clinical implications of increased strut thickness in the management
of long lesions & coronary bifurcations may have important clinical (e.g. duration of
antiplatelet therapy) and design considerations (e.g. longer devices & the requirement of
dedicated bifurcation devices to avoid overlapping the device) for current and future
devices with bioresorbable platforms.
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ABSORB EXTEND: An Interim Report on the 12-month Clinical Outcomes
from the First 250 Patients Enrolled
Antonio Bartorelli1
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Background: The safety and performance of the Absorb Bioresorbable Vascular
Scaffold (BVS) System (Abbott Vascular, Santa Clara, CA) has been previously
established in 131 patients from Cohort A and Cohort B of the First-in-Man ABSORB
trial. Results out to 2 years have been presented in 101 patients from the ABSORB Cohort
B trial. At 12 months, the MACE rate was 6.9%, with no scaffold thrombosis reported,
which was sustained out to 2 years with a MACE rate of 9.0%. Following this trial,
ABSORB EXTEND was initiated as a global continued access study (outside of the US)
to expand experience with the Absorb BVS to different geographies. Additionally, patients
were treated for longer coronary lesions than those in the ABSORB trial using either
longer scaffold lengths or planned overlap of the Absorb BVS.
Methods: ABSORB EXTEND is a prospective, single-arm, open-label clinical study that
is planning to enroll up to 1,000 subjects at up to 100 sites. Included are patients with
lesions  28 mm in length and reference vessel diameter of 2.0 - 3.3 mm (as assessed by
on-line QCA or IVUS). Treatment of a maximum of two de novo native coronary artery
lesions, each in a different epicardial vessel, is permitted.
Results: Interim 12-month data in the first 250 patients enrolled in ABSORB EXTEND
will be available for the first time in October 2012 and will provide additional data on the
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safety and performance of the Absorb BVS in a larger population of patients, including
those with longer lesions and dual vessel treatment. Clinical composites and component
end points will be presented out to 12 months.
Conclusions: Clinical and angiographic outcomes from the First-in-Man ABSORB trial
have demonstrated the safety and efficacy of the Absorb BVS in lesions 14 mm. Interim
outcomes in 250 patients at 12 months, (the largest patient cohort reported at this time
point to date) from ABSORB EXTEND will provide further insight into the longer-term
safety and efficacy of the ABSORB BVS in patients with longer lesions.
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Artery Lesions: 3 Year Clinical Results of the ABSORB Cohort B1 Trial
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Background: The ABSORB Cohort A trial results demonstrated the safety of Absorb
BVS (Abbott Vascular, Santa Clara, CA, USA) in 30 patients with single de novo native
coronary artery lesions, with a low long-term MACE rate at 5 years (3.4%) and no
scaffold thrombosis. The ABSORB Cohort B trial, a continuation of that assessment with
a modified Absorb BVS, enrolled 101 patients at 12 sites in European and Asia Pacific
regions between March and November 2009.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups, Cohort
B1 (45 patients, enrolment from March 19 to August 20, 2009) having angiographic
follow-up performed at 180 days and 2 years and Cohort B2 (56 patients, enrolment from
August 21 to November 6, 2009) having angiographic follow-up performed at 1 and 3
years. Key clinical endpoints include ischemia driven MACE (ID-MACE) and its
components at 30 days, 6, 9 and 18 months, and 1, 2, 3, 4 and 5 years.
Results: In Cohort B, clinical data up to 2 years for the full cohort of 101 patients (Group
B1 and B2) are currently available and are summarized hereafter. The mean age was 62
years, 72% of patients were male, 17% of patients were current tobacco users. Patients
with diabetes: 17%, hypertension: 66%, hypercholesterolemia: 85%, family history of
CAD: 55%, stable angina: 68%, of which15% having stable angina with CCS classifi-
cation of III or IV. Patients with unstable angina: 15%, 2% with unstable angina of
Braunwald Class III. Lesion location was RCA (33%), LAD (43%), LCX (22%) and
Ramus (1%), with ACC/AHA lesion classification of A for 1% of patients, B1 for 55%,
B2 for 40% and C for 4%. In these 101 patients, 2 year results showed an ID-MACE rate
of 9.0% and no scaffold thrombosis. The angiographic results for Cohort B1 demonstrated
an angiographic late loss at 180 days of 0.19 mm and at 2 years of 0.27 mm. This value
of 0.27 mm at 2 years was similar to the late loss in Cohort B2 at 1 year (0.27 mm).The
3-year clinical results for Cohort B1 will be presented. Clinical and imaging results at
3-year for all patients in Cohort B will be available in 2013.
Conclusions: Three year clinical follow-up data of Cohort B1 is pending.
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Background: Recent reports have demonstrated that the healing process after the
deployment of a bioresorbable scaffold (BRS) leads to the development of fibromuscular
tissue that covers the vessel wall. However the distribution of the neointima over the
vessel wall remains unclear. In this study we evaluated the circumferential distribution of
the neointima tissue developed after a BRS implantation at 6 months and at 2 years
follow-up.
Methods: We analyzed data from 20 patients who had undergone an Abbott Vascular
BRS 1.1 implantation and have been investigated with optical coherence tomography
(OCT) at baseline, immediate after scaffold implantation, at 6 months and at 2 years
follow-up. In the acquired sequences an experienced operator detected the luminal and the
scaffold borders and then the circumferential thickness of the neointima was measured at
1 degree interval with the use of dedicated software. The symmetry of the neointima tissue
was defined as the ratio minimum/maximum neointima thickness.
Results: The lumen area decreased at 6 months but there was no difference between the
2 follow-up time points [7.56 (6.37-7.98)mm2 vs. 6.28 (4.89-7.05)mm2 at 6 months,
P0.001; vs. 6.06 (5.01-7.11)mm2 at 2 years, P0.851]. The mean neointima thickness
was increased at 2 years [192 (174-232) m vs. 254 (230-288) m, P0.0001] and the
symmetry index of the neointima was higher [0.06 (0.02-0.09) vs. 0.27 (0.24-0.34),
P0.0001] at this time point suggesting a more homogenous distribution. Full circum-
ferential coverage of the vessel wall by neointima tissue was seen in 90% of the studied
frames, at 2 years. In 79% of the analyzed frames the minimum neointima thickness was
65m at this time point.
Conclusions: We analyzed, for the first time serial OCT data, to investigate the
neointima evolution and its circumferential distribution after a BRS implantation. It was
found that a thick neointima tissue develops which at 2 years covers, in most of the
frames, the whole circumference of the vessel wall. Hence, the Abbott Vascular BRS 1.1
can be regarded as a potentially useful device for the passivation of high risk plaques.
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Background: Multimodality imaging of the first-in-man trial using fully resorbable
everolimus-eluting scaffold (BVS, Abbott Vascular, Santa Clara, USA) demonstrated at 2
years the bioresorption of the device while preventing restenosis. Nevertheless, the
long-term safety and efficacy of this therapy remain to be documented.
Methods: In the ABSORB cohort A trial, 30 patients with a single de novo coronary
artery lesion were treated with the fully resorbable everolimus-eluting ABSORB scaffold
(Abbott vascular, CA, US). The patients underwent MSCT imaging at 5 years. Acquired
MSCT data was analyzed in an independent corelab (Cardialysis, Netherlands) for
quantitative analysis of lumen dimensions, and was further processed for calculation of
fractional flow reserve in another independent corelab (Heart Flow, CA, USA).
Results: Five-year clinical follow-up is available in 29 patients since one patient
withdrew consent after 6 months. At 46 days, one patient experienced a single episode of
chest pain and underwent a target lesion revascularization with slight troponin rise after
the procedure. At 5 years, the ID-MACE of 3.4% remained unchanged. Clopidogrel was
discontinued in all but one patient. There has been no stent thrombosis reported. Two
non-cardiac deaths were reported; one from duodenal perforation, the other from
Hodgkin’s disease. At 5 years, 18 patients underwent MSCT scan. All scaffolds were
patent with an average minimal lumen area of 3.41.4 mm2 with an average area stenosis
of 2923%. Out of 18 cases, non-invasive FFR analysis was feasible in 13 cases. The
median of FFR-CT in the distal segment was 0.83 [interquartile range: 0.81, 0.94].
Conclusions: Five-year clinical results have demonstrated a sustained low MACE rate
without any late complication such as stent thrombosis. MSCT assessment was feasible
after placement of Bioresorbable scaffold and non-invasive FFR can be also assessed in
the selected cases.
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Background: In order to assess the intermediate term safety, clinical performance and
the bioabsorption process of the Paclitaxel-Eluting Bioabsorbable Magnesium Scaffold
(DREAMS) 2-year clinical data of cohort 1 and multi-modality imaging outcomes up to
1 year follow-up are reported.
Methods: Forty-six subjects were enrolled in the first-in-man BIOSOLVE-I study, and
assigned to two different cohorts with different invasive follow-up schedules. Clinical
follow-up for both cohorts is scheduled at 1, 6, 12, 24 and 36 months, angiographic and
IVUS follow-up for cohort 1 at 6 months and for cohort 2 at 12 months. A subgroup of
patients underwent OCT and vasomotion testing. The primary endpoint is Target Lesion
Failure (TLF), defined as the composite of cardiac death, target vessel myocardial
infarction and clinically driven target lesion failure, at 6 months for cohort 1 and at 12
month for cohort 2.
Results: Clinical: TLF rate at 12-month was 7.0% including two clinically driven target
lesion revascularizations and one peri-procedural target vessel myocardial infarction
occurring during 12-month follow-up angiography. No cardiac death or scaffold throm-
bosis was observed. Twenty-four month clinical data of cohort 1 will be available upon
presentation. Angiographic: In-scaffold late lumen loss was 0.520.39 at 12 months.
Vasoconstriction after acetylcholine was documented by quantitative coronary angiogra-
phy (delta-10.04%; p0.0008) followed by vasodilatation after nitroglycerine
(delta8.69%; p0.0001) which demonstrates the uncaging aspect of the absorption
process already at 6-month follow-up with no further change at the 12-month follow-up.
IVUS: Six-month virtual histology (VH) data showed a significant decrease in the dense
calcium by 39.5% (p0.0015) which remains stable until 12-month follow-up. This
decrease of dense calcium is interpreted as a surrogate assessment for the bioabsorption
process of the scaffold material.
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